{"title":"急性髓性白血病:一种不断变化的疾病","authors":"Nancy M. Nix, Allyson Price","doi":"10.6004/jadpro.2019.10.8.12","DOIUrl":null,"url":null,"abstract":"Abstract Acute myeloid leukemia is the most common form of acute leukemia in adults. In recent years, there has been robust characterization of molecular targets for drug development, leading to the U.S. Food & Drug Administration approval of numerous new treatments during 2017 and 2018. In light of these new approvals, this article provides an update for advanced practitioners on risk stratification, which is critical for guiding treatment selection.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"10 1","pages":"4 - 8"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Acute Myeloid Leukemia: An Ever-Changing Disease\",\"authors\":\"Nancy M. Nix, Allyson Price\",\"doi\":\"10.6004/jadpro.2019.10.8.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Acute myeloid leukemia is the most common form of acute leukemia in adults. In recent years, there has been robust characterization of molecular targets for drug development, leading to the U.S. Food & Drug Administration approval of numerous new treatments during 2017 and 2018. In light of these new approvals, this article provides an update for advanced practitioners on risk stratification, which is critical for guiding treatment selection.\",\"PeriodicalId\":94110,\"journal\":{\"name\":\"Journal of the advanced practitioner in oncology\",\"volume\":\"10 1\",\"pages\":\"4 - 8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the advanced practitioner in oncology\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2019.10.8.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the advanced practitioner in oncology","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.6004/jadpro.2019.10.8.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract Acute myeloid leukemia is the most common form of acute leukemia in adults. In recent years, there has been robust characterization of molecular targets for drug development, leading to the U.S. Food & Drug Administration approval of numerous new treatments during 2017 and 2018. In light of these new approvals, this article provides an update for advanced practitioners on risk stratification, which is critical for guiding treatment selection.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
